Copyright
©2013 Baishideng Publishing Group Co.
World J Hepatol. Apr 27, 2013; 5(4): 182-188
Published online Apr 27, 2013. doi: 10.4254/wjh.v5.i4.182
Published online Apr 27, 2013. doi: 10.4254/wjh.v5.i4.182
Table 3 Treatment outcomes in treatment-naive and treatment-experienced patients according to platelet counts at baseline
< 130000/μL | ≥130000/μL | P value | |
Proportion of SVR-archived in treatment-naive patients | |||
Total patients | 10/27 (37.0%) | 62/100 (62.0%) | 0.020 |
48 wk treatment | 7/20 (35.0%) | 44/69 (63.8%) | 0.022 |
72 wk treatment | 3/7 (42.9%) | 18/31 (58.1%) | NS |
Treatment-experienced patients | |||
Total patients | 7/24 (29.2%) | 20/45 (44.4%) | NS |
48 wk treatment | 7/20 (33.3%) | 9/21 (42.9%) | NS |
72 wk treatment | 2/9 (22.2%) | 11/24 (45.8%) | NS |
- Citation: Kanda T, Kato K, Tsubota A, Takada N, Nishino T, Mikami S, Miyamura T, Maruoka D, Wu S, Nakamoto S, Arai M, Fujiwara K, Imazeki F, Yokosuka O. Platelet count and sustained virological response in hepatitis C treatment. World J Hepatol 2013; 5(4): 182-188
- URL: https://www.wjgnet.com/1948-5182/full/v5/i4/182.htm
- DOI: https://dx.doi.org/10.4254/wjh.v5.i4.182